glasdegib: Clinical Trials

11 trials of glasdegib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 3 terminated, 1 active not recruiting, 1 unknown. 11 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 211Completed 6, Terminated 3, Active not recruiting 1, Unknown 1
Phase 14Completed 2, Terminated 1, Unknown 1

Follow glasdegib: new trials by email Literature Review of glasdegib trials Research Report on glasdegib

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
Glasdegib, CPX-351 - Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Phase 2Active not recruitingUniversity of California, Irvine302020-02-192026-07-16
GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia
Glasdegib, Decitabine - ACUTE MYELOID LEUKEMIA
Phase 2TerminatedYale University12019-12-062021-10-15
Glasdegib for Chronic Graft-Versus-Host Disease
Glasdegib - Chronic Graft Versus Host Disease, Fasciitis
Phase 1 / Phase 2TerminatedFred Hutchinson Cancer Center152019-12-032024-10-29
Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma
PF-04449913, Temozolomide Oral Capsule - Glioblastoma
Phase 1 / Phase 2CompletedGrupo Español de Investigación en Neurooncología752018-03-152024-03-28
Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease
Glasdegib - Sclerodermoid Chronic Graft-Versus-Host Disease (Disorder)
Phase 1 / Phase 2UnknownGrupo Espanol de trasplantes hematopoyeticos y terapia celular212018-01-092022-03-17
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
Anti-OX40 Agonist Monoclonal Antibody PF-04518600, Avelumab, Azacitidine - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Phase 1 / Phase 2CompletedM.D. Anderson Cancer Center502017-12-272023-09-05
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Cytarabine, Decitabine, Idarubicin - Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Phase 2CompletedUniversity of Nebraska752017-07-072026-03-10
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Glasdegib (PF-04449913), Placebo - Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Phase 2TerminatedPfizer212014-10-062019-01-17
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)
PF-04449913 - Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)
Phase 2CompletedH. Lee Moffitt Cancer Center and Research Institute352013-08-292021-06-14
PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
PF-04449913 - Adult Acute Myeloid Leukemia in Remission, Recurrent Adult Acute Myeloid Leukemia
Phase 2CompletedUniversity of Colorado, Denver312013-04-292022-01-25
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
PF-04449913, Low dose ARA-C (LDAC), Decitabine - Acute Myeloid Leukemia
Phase 2CompletedPfizer2552012-06-272020-03-03

Conditions studied

Leukemia, Myeloid, Acute (6)  ·  Myelodysplastic Syndromes (2)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Fasciitis (1)  ·  Glioblastoma (1)  ·  Graft vs Host Disease (1)  ·  Leukemia (1)  ·  Leukemia, Myeloid (1)  ·  Leukemia, Myelomonocytic, Chronic (1)  ·  Primary Myelofibrosis (1)

Sponsors

Pfizer (2)  ·  Fred Hutchinson Cancer Center (1)  ·  Grupo Espanol de trasplantes hematopoyeticos y terapia celular (1)  ·  Grupo Español de Investigación en Neurooncología (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  M.D. Anderson Cancer Center (1)  ·  University of California, Irvine (1)  ·  University of Colorado, Denver (1)  ·  University of Nebraska (1)  ·  Yale University (1)

Countries

United States (9)  ·  Spain (3)  ·  Canada (1)  ·  Germany (1)  ·  Italy (1)  ·  Japan (1)  ·  Poland (1)

Top investigators

Amer M Zeidan, MBBS (1)  ·  Daniel A Pollyea, MD, MS (1)  ·  Deepa Jeyakumar, MD (1)  ·  Jeffrey Lancet, M.D. (1)  ·  Naval G Daver (1)  ·  Stephanie Lee (1)  ·  Vijaya R Bhatt, MD (1)

Results publications

PMID 37698881, PMID 29463550, PMID 30074259, PMID 30555165, PMID 32664995, PMID 32885274, PMID 33740113, PMID 35442137, PMID 35450817, PMID 38000343, PMID 40298352

NIH funding

2017 (2), 2014 (1), P30CA036727 (1)